MX2007005115A - Combinacion de un inhibidor de proteina cinasa src y un inhibidor de proteina cinasa bcr-abl para el tratamiento de enfermedades proliferativas. - Google Patents

Combinacion de un inhibidor de proteina cinasa src y un inhibidor de proteina cinasa bcr-abl para el tratamiento de enfermedades proliferativas.

Info

Publication number
MX2007005115A
MX2007005115A MX2007005115A MX2007005115A MX2007005115A MX 2007005115 A MX2007005115 A MX 2007005115A MX 2007005115 A MX2007005115 A MX 2007005115A MX 2007005115 A MX2007005115 A MX 2007005115A MX 2007005115 A MX2007005115 A MX 2007005115A
Authority
MX
Mexico
Prior art keywords
inhibitor
treatment
combination
bcr
proliferative diseases
Prior art date
Application number
MX2007005115A
Other languages
English (en)
Inventor
Francis Y Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2007005115A publication Critical patent/MX2007005115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se describe una combinacion y metodos que son utiles para el tratamiento del cancer y/o leucemia.
MX2007005115A 2004-11-04 2005-11-04 Combinacion de un inhibidor de proteina cinasa src y un inhibidor de proteina cinasa bcr-abl para el tratamiento de enfermedades proliferativas. MX2007005115A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62493704P 2004-11-04 2004-11-04
US63212204P 2004-12-01 2004-12-01
US64972205P 2005-02-03 2005-02-03
US70362805P 2005-07-29 2005-07-29
PCT/US2005/040145 WO2006052810A2 (en) 2004-11-04 2005-11-04 Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
MX2007005115A true MX2007005115A (es) 2007-06-26

Family

ID=36337059

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005115A MX2007005115A (es) 2004-11-04 2005-11-04 Combinacion de un inhibidor de proteina cinasa src y un inhibidor de proteina cinasa bcr-abl para el tratamiento de enfermedades proliferativas.

Country Status (13)

Country Link
US (2) US20060094728A1 (es)
EP (1) EP1812432A4 (es)
JP (1) JP2008519049A (es)
KR (1) KR20070073864A (es)
AR (1) AR053984A1 (es)
AU (1) AU2005304863A1 (es)
BR (1) BRPI0515721A (es)
CA (1) CA2586649A1 (es)
MX (1) MX2007005115A (es)
NO (1) NO20072179L (es)
RU (1) RU2007120710A (es)
TW (1) TW200628156A (es)
WO (1) WO2006052810A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009721A (pt) 1999-04-15 2002-02-13 Bristol Myers Squibb Co Inibidores de tirosina quinase de proteìna cìclica
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
ATE505192T1 (de) * 2005-06-09 2011-04-15 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein
US20070123539A1 (en) 2005-10-20 2007-05-31 University Of South Florida Treatment of Restenosis and Stenosis with Dasatinib
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
JP2010539156A (ja) † 2007-10-23 2010-12-16 テバ ファーマシューティカル インダストリーズ リミティド ダサチニブ多形体およびその調製プロセス
CN101812060B (zh) * 2010-02-02 2011-08-17 南京卡文迪许生物工程技术有限公司 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物
CN101891738B (zh) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
JP5589097B2 (ja) * 2010-02-08 2014-09-10 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
CN102643275B (zh) * 2011-02-21 2016-04-20 江苏先声药物研究有限公司 一种达莎替尼n-6晶型新的制备方法
CN104788446A (zh) * 2011-06-24 2015-07-22 南京圣和药业股份有限公司 无水达沙替尼的制备及精制方法
JP2017506259A (ja) * 2014-02-03 2017-03-02 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 幹細胞を枯渇させるためのカゼインキナーゼｉ阻害剤の使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
BR0009721A (pt) * 1999-04-15 2002-02-13 Bristol Myers Squibb Co Inibidores de tirosina quinase de proteìna cìclica
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7169771B2 (en) * 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
EP2260849A1 (en) * 2004-01-21 2010-12-15 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection

Also Published As

Publication number Publication date
NO20072179L (no) 2007-05-31
TW200628156A (en) 2006-08-16
EP1812432A4 (en) 2009-11-25
AU2005304863A1 (en) 2006-05-18
US20090093495A1 (en) 2009-04-09
US20060094728A1 (en) 2006-05-04
CA2586649A1 (en) 2006-05-18
EP1812432A2 (en) 2007-08-01
JP2008519049A (ja) 2008-06-05
WO2006052810A2 (en) 2006-05-18
BRPI0515721A (pt) 2008-08-05
RU2007120710A (ru) 2008-12-10
AR053984A1 (es) 2007-05-30
WO2006052810A3 (en) 2007-02-08
KR20070073864A (ko) 2007-07-10

Similar Documents

Publication Publication Date Title
TW200628156A (en) Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
TW200801008A (en) Protein kinase inhibitors
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
ZA200600176B (en) Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2006089087A9 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
EP1774043A4 (en) COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
HK1117780A1 (en) Compounds and methods for the treatment of cancer
UA88655C2 (ru) S-миртазапин для лечения прилива крови
ZA200801332B (en) Pentacyclic kinase inhibitors
HK1115528A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
WO2008121467A3 (en) Combination therapy for treating cancer
PL1740200T3 (pl) IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią
EP2099458A4 (en) COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS
WO2008103431A3 (en) Dnai - liposomes
PL1965790T3 (pl) Metabolity analogów wortmaniny i sposoby ich stosowania
TW200714284A (en) Novel method
WO2004075848A3 (en) Antitumor inhibitors and use thereof
WO2004073631A3 (en) Combination therapy for the treatment of neoplasms
WO2006113536A3 (en) Use of pt523 for treating cancers

Legal Events

Date Code Title Description
FA Abandonment or withdrawal